Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn down syndrome mice

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676 · see citing works

Anorexigenic and Orexigenic Hormone Modulation of Mammalian Target of Rapamycin Complex 1 Activity and the Regulation of Hypothalamic Agouti-Related Protein mRNA Expression

Watterson, K. R., Bestow, D., Gallagher, J. R., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2012) · Neurosignals · doi:10.1159/000334144 · Cited by 3,395 · see citing works

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668 · see citing works

The selectivity of protein kinase inhibitors: a further update

Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I. V., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,522 · see citing works

Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease

Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492 · see citing works

Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.

Grundke, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38495-8 · Cited by 1,780 · see citing works

The specificities of protein kinase inhibitors: an update

BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · see citing works

Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome

Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · see citing works

Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau

Goedert, M., Wischik, C. M., Crowther, R. A., Walker, J. E., & Klug, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.11.4051 · Cited by 1,134 · see citing works

O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease

Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., & Gong, C.-X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400348101 · Cited by 775 · see citing works

Structure and novel exons of the human .tau. gene

Andreadis, A., Brown, W. M., & Kosik, K. S. (1992) · Biochemistry · doi:10.1021/bi00158a027 · Cited by 625 · see citing works

Developmentally regulated expression of specific tau sequences

Kosik, K. S., Orecchio, L. D., Bakalis, S., & Neve, R. L. (1989) · Neuron · doi:10.1016/0896-6273(89)90077-9 · Cited by 598 · see citing works

Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue

Suganuma, M. (1998) · Carcinogenesis · doi:10.1093/carcin/19.10.1771 · Cited by 527 · see citing works

Mutations causing neurodegenerative tauopathies

Goedert, M., & Jakes, R. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.08.007 · Cited by 438 · see citing works

Alzheimer's disease in Down's syndrome: Clinicopathologic studies

Wisniewski, K. E., Dalton, A. J., McLachlan, D. R. C., Wen, G. Y., & Wisniewski, H. M. (1985) · Neurology · doi:10.1212/wnl.35.7.957 · Cited by 417 · see citing works

Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome

Altafaj, X. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.18.1915 · Cited by 396 · see citing works

Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: Findings from the Nun Study

Riley, K. P., Snowdon, D. A., & Markesbery, W. R. (2002) · Annals of Neurology · doi:10.1002/ana.10161 · Cited by 392 · see citing works

Sequence Characteristics, Subcellular Localization, and Substrate Specificity of DYRK-related Kinases, a Novel Family of Dual Specificity Protein Kinases

Becker, W. B., Weber, Y. G., Wetzel, K., EIRMBTER, K., Tejedor, F. J., & Joost, H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25893 · Cited by 285 · see citing works

Epigallocatechin‐3‐gallate, a DYRK1A inhibitor, rescues cognitive deficits in D own syndrome mouse models and in humans

de la Torre, R., Sola, S. D., Pons‐Espinal, M., Duchon, A., de Lagrán, M. M., Farré, M., Fitó, M., Benejam, B., Langohr, K., Rodríguez, J. C., et al. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201300325 · Cited by 283 · see citing works

Overexpression of Dyrk1A contributes to neurofibrillary degeneration in down syndrome

Liu, F., Liang, Z., Wegiel, J., Hwang, Y., Iqbal, K., Grundke‐Iqbal, I., Ramakrishna, N., & Gong, C. (2008) · The FASEB Journal · doi:10.1096/fj.07-104539 · Cited by 272 · see citing works

Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis

Alafuzoff, I. I., Iqbal, K., Fridén, H., Adolfsson, R., & Winblad, B. G. (1987) · Acta Neuropathologica · doi:10.1007/bf00688184 · Cited by 265 · see citing works

Dyrk, a Dual Specificity Protein Kinase with Unique Structural Features Whose Activity Is Dependent on Tyrosine Residues between Subdomains VII and VIII

Kentrup, H., Becker, W. B., Heukelbach, J., Wilmes, A., Schürmann, A., Huppertz, C., Kainulainen, H., & Joost, H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3488 · Cited by 259 · see citing works

DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects

Ahn, K.-J., Jeong, H. K., Choi, H.-S., Ryoo, S.-R., Kim, Y. J., Goo, J.-S., Choi, S.-Y., Han, J.-S., Ha, I., & Song, W.-J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.006 · Cited by 220 · see citing works

Pharmacokinetics of (−)-Epigallocatechin-3-gallate in Conscious and Freely Moving Rats and Its Brain Regional Distribution

Lin, L.-C., Wang, M.-N., Tseng, T.-Y., Sung, & Tsai, T. (2007) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf062816a · Cited by 211 · see citing works

Interplay between SRPK and Clk/Sty Kinases in Phosphorylation of the Splicing Factor ASF/SF2 Is Regulated by a Docking Motif in ASF/SF2

Ngo, J. C. K., Chakrabarti, S., Ding, J., Velazquez-Dones, A., Nolen, B. J., Aubol, B. E., Adams, J. A., Fu, X., & Ghosh, G. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.08.025 · Cited by 207 · see citing works

Phosphorylation of tau by glycogen synthase kinase-3β in intact mammalian cells: The effects on the organization and stability of microtubules

Lovestone, S., Hartley, C. L., Pearce, J., & Anderton, B. H. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00126-1 · Cited by 201 · see citing works

Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down Syndrome

Shi, J., Zhang, T., Zhou, C., Chohan, M. O., Gu, X., Węgiel, J., Zhou, J., Hwang, Y., Iqbal, K., Grundke, I., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802645200 · Cited by 179 · see citing works

DYRK1A accumulates in splicing speckles through a novel targeting signal and induces speckle disassembly

Álvarez‐Fernández, M., Estivill, X., & de la Luna, S. (2003) · Journal of Cell Science · doi:10.1242/jcs.00618 · Cited by 161 · see citing works

Isoforms changes of tau protein during development in various species

Takuma, H., Arawaka, S., & Mori, H. (2003) · Developmental Brain Research · doi:10.1016/s0165-3806(03)00056-7 · Cited by 157 · see citing works

The Subcellular Localization of SF2/ASF Is Regulated by Direct Interaction with SR Protein Kinases (SRPKs)

Koizumi, J., Okamoto, Y., Onogi, H., Mayeda, A., Krainer, A. R., & Hagiwara, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.11125 · Cited by 140 · see citing works

Characterization of Cyclin L2, a Novel Cyclin with an Arginine/Serine-rich Domain

de Graaf, K., Hekerman, P., Spelten, O., Herrmann, A., Packman, L. C., Büssow, K., Müller-Newen, G., & Becker, W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310794200 · Cited by 124 · see citing works

The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site

de Graaf, K., Czajkowska, H., Rottmann, S., Packman, L. C., Lilischkis, R., Lüscher, B., & Becker, W. B. (2006) · BMC Biochemistry · doi:10.1186/1471-2091-7-7 · Cited by 109 · see citing works

Regulation of alternative splicing of tau exon 10

Qian, W., & Liu, F. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1411-2 · Cited by 105 · see citing works

Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A

Wu, Q., Liang, H., Shi, J., Jin, N., Grundke, I., Iqbal, K., Gong, C., & Liu, F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr195 · Cited by 100 · see citing works

Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A) Modulates Serine/Arginine-rich Protein 55 (SRp55)-promoted Tau Exon 10 Inclusion

Yin, X., Jin, N., Gu, J., Shi, J., Zhou, J., Gong, C., Iqbal, K., Grundke, I., & Liu, F. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.355412 · Cited by 93 · see citing works

Prefrontal Deficits in a Murine Model Overexpressing the Down Syndrome Candidate GeneDyrk1a

Thomazeau, A., Lassalle, O., Iafrati, J., Souchet, B., Guedj, F., Janel, N., Chavis, P., Delabar, J. M., & Manzoni, O. J. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2852-13.2014 · Cited by 93 · see citing works

Cyclic AMP-dependent Protein Kinase Regulates the Alternative Splicing of Tau Exon 10

Shi, J., Qian, W., Yin, X., Iqbal, K., Grundke, I., Gu, X., Ding, F., Gong, C., & Liu, F. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.204453 · Cited by 87 · see citing works

Cell type- and brain structure-specific patterns of distribution of minibrain kinase in human brain

Węgiel, J., Kuchna, I., Nowicki, K., Frackowiak, J., Dowjat, K., Silverman, W. P., Reisberg, ‌., de Leon, M. J., Wısnıewskı, T., Adayev, T., et al. (2004) · Brain Research · doi:10.1016/j.brainres.2004.03.008 · Cited by 80 · see citing works

Uptake and distribution of catechins in fetal organs following in utero exposure in rats

Chu, K. O., Wang, C. C., Chu, C. Y., Choy, K. W., Pang, C., & Rogers, M. S. (2006) · Human Reproduction · doi:10.1093/humrep/del353 · Cited by 80 · see citing works

Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of down syndrome

Altafaj, X., Martín, E. D., Ortiz-Abalia, J., Valderrama, A., Lao-Peregrín, C., Dierssen, M., & Fillat, C. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.11.017 · Cited by 75 · see citing works

Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I

Jin, N., Yin, X., Gu, J., Zhang, X., Shi, J., Qian, W., Ji, Y., Cao, M., Gu, X., Ding, F., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.645507 · Cited by 71 · see citing works

Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations

Toiber, D., Azkona, G., Ben‐Ari, S., Torán, N., Soreq, H., & Dierssen, M. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.06.011 · Cited by 55 · see citing works

Arginine/Serine-rich Protein Interaction Domain-dependent Modulation of a Tau Exon 10 Splicing Enhancer

D’Souza, I., & Schellenberg, G. D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505809200 · Cited by 49 · see citing works

Down syndrome

Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0143-7 · Cited by 964 · see citing works

DYRK1A and cognition: A lifelong relationship

Arbonés, M. L., Thomazeau, A., Nakano-Kobayashi, A., Hagiwara, M., & Delabar, J. M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.010 · Cited by 165 · see citing works

Type 2 Diabetes Mellitus and Alzheimer’s Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets

Hamzé, R., Delangre, E., Tolu, S., Moreau, M., Janel, N., Bailbé, D., & Movassat, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315287 · Cited by 163 · see citing works

Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer’s Disease

Colacurcio, D. J., Pensalfini, A., Jiang, Y., & Nixon, R. A. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.001 · Cited by 167 · see citing works

Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview

Lindberg, M. F., & Meijer, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116047 · Cited by 123 · see citing works

Amyloid-beta and tau protein beyond Alzheimer’s disease

Abyadeh, M., Gupta, V., Paulo, J. A., Mahmoudabad, A. G., Shadfar, S., Mirshahvaladi, S., Gupta, V. B., Nguyen, C. T. O., Finkelstein, D. I., You, Y., et al. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.386406 · Cited by 121 · see citing works

Involvement of calpain in the neuropathogenesis of Alzheimer’s disease

Mahaman, Y. A. R., Huang, F., Afewerky, H. K., Salissou, M. T. M., Bishwajit, G., & Wang, X. (2018) · Medicinal Research Reviews · doi:10.1002/med.21534 · Cited by 107 · see citing works

Pathological Changes of Tau Related to Alzheimer’s Disease

Chu, D., & Liu, F. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00457 · Cited by 103 · see citing works

Mitochondria as pharmacological targets in Down syndrome

Valenti, D., Braidy, N., Rasmo, D. D., Signorile, A., Rossi, L., Atanasov, A. G., Volpicella, M., Henrion‐Caude, A., Nabavi, S. M., & Vacca, R. A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.014 · Cited by 96 · see citing works

DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis

Laham, A., Saber-Ayad, M., & El-Awady, R. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03626-4 · Cited by 1 · see citing works

DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3

Bhansali, R. S., Rammohan, M., Lee, P., Laurent, A. P., Wen, Q., Suraneni, P. K., Yip, B. H., Tsai, Y.-C., Jenni, S., Bornhauser, B. C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135937 · Cited by 92 · see citing works

mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia

Di Domenico, F., Tramutola, A., Foppoli, C., Head, E., Perluigi, M., & Butterfield, D. A. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.009 · Cited by 89 · see citing works

Down syndrome: Neurobiological alterations and therapeutic targets

Vacca, R. A., Bawari, S., Valenti, D., Tewari, D., Nabavi, S. F., Shirooie, S., Sah, A. N., Volpicella, M., Braidy, N., & Nabavi, S. M. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.01.001 · Cited by 90 · see citing works

Exosomal biomarkers in Down syndrome and Alzheimer's disease

Hamlett, E. D., Ledreux, A., Potter, H., Chial, H. J., Patterson, D., Espinosa, J. M., Bettcher, B. M., & Granholm, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.028 · Cited by 78 · see citing works

Prenatal treatment with EGCG enriched green tea extract rescues GAD67 related developmental and cognitive defects in Down syndrome mouse models

Souchet, B., Duchon, A., Gu, Y., Dairou, J., Chevalier, C., Daubigney, F., Nalesso, V., Créau, N., Yu, Y., Janel, N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40328-9 · Cited by 54 · see citing works

Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer’s Disease Drug Candidate

Lindberg, M. F., Deau, E., Miege, F., Greverie, M., Roche, D., George, N. S., George, P. G., Merlet, L., Gavard, J., Brugman, S. J. T., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01888 · Cited by 55 · see citing works

DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective

Pathak, A., Rohilla, A., Gupta, T., Akhtar, M. J., Haider, M. R., Sharma, K., Haider, K., & Yar, M. S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.093 · Cited by 54 · see citing works

Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases

Lindberg, M. F., Deau, E., Arfwedson, J., George, N. S., George, P. G., Alfonso, P., Corrionero, A., & Meijer, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02068 · Cited by 52 · see citing works

Function and inhibition of DYRK1A: Emerging roles of treating multiple human diseases

Yang, Y., Fan, X., Liu, Y., Ye, D., Liu, C., Yang, H., Su, Z., Zhang, Y., & Liu, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115521 · Cited by 43 · see citing works

Systems Biology Methods for Alzheimer’s Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials

Castrillo, J. I., Lista, S., Hampel, H. J., & Ritchie, C. W. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7704-8_3 · Cited by 44 · see citing works

Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult down syndrome mice

Goodlett, C. R., Stringer, M., LaCombe, J., Patel, R., Wallace, J. M., & Roper, R. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-67133-z · Cited by 43 · see citing works

Ca2+/calmodulin-dependent protein kinase II regulation by inhibitor 1 of protein phosphatase 1 alleviates necroptosis in high glucose-induced cardiomyocytes injury

Sun, L., Chen, Y., Luo, H., Xu, M., Meng, G., & Zhang, W. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.02.022 · Cited by 40 · see citing works

Extracellular Vesicles in CNS Developmental Disorders

Gomes, A. R., Sangani, N. B., Fernandes, T. G., Diogo, M. M., Curfs, L., & Reutelingsperger, C. P. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249428 · Cited by 40 · see citing works

Proline Hydroxylation Primes Protein Kinases for Autophosphorylation and Activation

Lee, S. B., Ko, A., Oh, Y. T., Shi, P., D’Angelo, F., Frangaj, B., Koller, A. A., Chen, E. I., Cardozo, T. J., Iavarone, A., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.06.021 · Cited by 38 · see citing works

The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives

Stagni, F., & Bartesaghi, R. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.903729 · Cited by 31 · see citing works

Human tau-overexpressing mice recapitulate brainstem involvement and neuropsychiatric features of early Alzheimer’s disease

Khan, K. M., Balasubramanian, N., Gaudencio, G., Wang, R., Selvakumar, G. P., Kolling, L. J., Pierson, S. R., Tadinada, S. M., Abel, T. G., Hefti, M. M., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01546-5 · Cited by 37 · see citing works

Structure–Activity Relationship in the Leucettine Family of Kinase Inhibitors

Tahtouh, T., Durieu, É., Villiers, B., Bruyère, C., Nguyen, T. L., Fant, X., Ahn, K. H., Khurana, L., Deau, E., Lindberg, M. F., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01141 · Cited by 31 · see citing works

DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease

de Souza, M. M., Cenci, A. R., Teixeira, K. F., Machado, V., Schülerb, M. C. G. M., Gonçalves, A. E., Dalmagro, A. P., Cazarin, C. A., Ferreira, L. L. G., de Oliveira, A. S., et al. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220620162018 · Cited by 30 · see citing works

Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer’s Disease and Down Syndrome

Meijer, L., Chrétien, E., & Ravel, D. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240078 · Cited by 30 · see citing works

Excess Folic Acid Supplementation Before and During Pregnancy and Lactation Activates Fos Gene Expression and Alters Behaviors in Male Mouse Offspring

Chu, D., Li, L., Jiang, Y., Jianxin, T., Ji, J., Zhang, Y., Jin, N., & Liu, F. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00313 · Cited by 30 · see citing works

Craniofacial dysmorphology in Down syndrome is caused by increased dosage of Dyrk1a and at least three other genes

Redhead, Y. T., Gibbins, D., Lana‐Elola, E., Watson-Scales, S., Dobson, L., Krause, M., Liu, K. J., Fisher, E., Green, J. B. A., & Tybulewicz, V. L. J. (2023) · Development · doi:10.1242/dev.201077 · Cited by 29 · see citing works

Therapeutic Potential of the Hsp90/Cdc37 Interaction in Neurodegenerative Diseases

Gracia, L., Lora, G., Blair, L. J., & Jinwal, U. K. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01263 · Cited by 28 · see citing works

Development of novel 2,4-bispyridyl thiophene–based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives

Darwish, S. S., Abdel‐Halim, M., Salah, M., Abadi, A., Becker, W. B., & Engel, M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.050 · Cited by 28 · see citing works

Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues

London, J., Rouch, C., Bui, L. C., Assayag, E., Souchet, B., Daubigney, F., Medjaoui, H., Luquet, S. H., Magnan, C., Delabar, J. M., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0591-6 · Cited by 27 · see citing works

Development of novel amide–derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification

Darwish, S. S., Abdel‐Halim, M., ElHady, A. K., Salah, M., Abadi, A., Becker, W. B., & Engel, M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.097 · Cited by 26 · see citing works

Inhibiting EGFR/HER-2 ameliorates neuroinflammatory responses and the early stage of tau pathology through DYRK1A

Kim, J., Kim, S.-J., Jeong, H.-R., Park, J.-H., Moon, M., & Hoe, H.-S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903309 · Cited by 23 · see citing works

Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches

Farrell, C., Mumford, P., & Wiseman, F. K. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.909669 · Cited by 22 · see citing works

Genetic Mapping of APP and Amyloid-β Biology Modulation by Trisomy 21

Mumford, P., Tosh, J., Anderle, S., Gkanatsiou Wikberg, E., Lau, G., Noy, S., Cleverley, K., Saito, T., Saido, T. C., Yu, E., et al. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.0521-22.2022 · Cited by 22 · see citing works

Rescue of deficits by Brwd1 copy number restoration in the Ts65Dn mouse model of Down syndrome

Fulton, S. L., Wenderski, W., Lepack, A. E., Eagle, A. L., Fanutza, T., Bastle, R. M., Ramakrishnan, A., Hays, E. C., Neal, A., Bendl, J. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34200-0 · Cited by 21 · see citing works

(−)-Epigallocatechin-3-gallate, a Polyphenol from Green Tea, Regulates the Liquid–Liquid Phase Separation of Alzheimer’s-Related Protein Tau

Chen, J., Ma, W., Yu, J., Wang, X., Qian, H., Li, P., Ye, H., Han, Y., Su, Z., Gao, M., et al. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c07799 · Cited by 20 · see citing works

microRNAs expression correlates with levels of APP, DYRK1A, hyperphosphorylated Tau and BDNF in the hippocampus of a mouse model for Down syndrome during ageing

Chaves, J. C. S., Machado, F. T., de Almeida, M. F., Bacovsky, T. B., & Ferrari, M. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134541 · Cited by 20 · see citing works

A novel de novo heterozygous DYRK1A mutation causes complete loss of DYRK1A function and developmental delay

Lee, K., Choi, M., Kwon, D.-W., Kim, D., Choi, J.-M., Kim, A., Ham, Y., Han, S., Cho, S., & Cheon, C. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-66750-y · Cited by 20 · see citing works

Non-invasive and high-throughput interrogation of exon-specific isoform expression

Truong, D. J., Phlairaharn, T., Eßwein, B., Gruber, C., Tümen, D., Baligács, E., Armbrust, N., Vaccaro, F. L., Lederer, E.-M., Beck, E. M., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00678-x · Cited by 20 · see citing works

Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D

Wang, P., Wang, L., Chen, L., & Sun, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-07655-1 · Cited by 18 · see citing works

Cell models for Down syndrome-Alzheimer’s disease research

Wu, Y., West, N. R., Bhattacharyya, A., & Wiseman, F. K. (2022) · Neuronal Signaling · doi:10.1042/ns20210054 · Cited by 17 · see citing works

Plasticity as a therapeutic target for improving cognition and behavior in Down syndrome

Martínez‐Cué, C., & Dierssen, M. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.11.001 · Cited by 15 · see citing works

Co-Expression of Three Wild-Type 3R-Tau Isoforms Induces Memory Deficit via Oxidation-Related DNA Damage and Cell Death: A Promising Model for Tauopathies

Xu, C., Guo, J., Li, L., Wang, X., Zhou, Q., Sun, D., Zhang, S., Li, S., Ye, J., Liu, Y., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-191132 · Cited by 14 · see citing works

Dual-specificity tyrosine phosphorylation-regulated kinase 1A promotes the inclusion of amyloid precursor protein exon 7

Chu, D., Lei, L., Gu, S. P., Liu, F., & Wu, F. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116233 · Cited by 13 · see citing works

Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model

Hawley, L. E., Stringer, M., Deal, A. J., Folz, A., Goodlett, C. R., & Roper, R. J. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106359 · Cited by 10 · see citing works

Unraveling the mechanistic interplay of mediators orchestrating the neuroprotective potential of harmine

Kadyan, P., & Singh, L. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00602-8 · Cited by 9 · see citing works

DYRK1A in the physiology and pathology of the neuron-astrocyte axis

Cisternas, P., Kim, J.-Y., Ashfeld, B. L., & Zartman, J. J. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1626062 · Cited by 7 · see citing works

Tau aggravates stress-induced anxiety by inhibiting adult ventral hippocampal neurogenesis in mice

Liu, H., Yang, Z., Yu, C., Dong, H., Wang, S., Wang, G., & Wang, D. (2022) · Cerebral Cortex · doi:10.1093/cercor/bhac312 · Cited by 7 · see citing works

Unlocking the Therapeutic Potential of the Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitors in Alzheimer’s Diseases

Karati, D., Meur, S., Saha, A., Saha, T., & Sen, A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04806-8 · Cited by 6 · see citing works

Kinase inhibition in Alzheimer’s disease

Bagheri, S., & Saboury, A. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91287-7.00003-x · Cited by 6 · see citing works

Protein quality control of DYRK family protein kinases by the Hsp90-Cdc37 molecular chaperone

Miyata, Y., & Nishida, E. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.119081 · Cited by 6 · see citing works

Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse model

Llambrich, S., Tielemans, B., Saliën, E., Atzori, M., Wouters, K., Bulck, V. V., Platt, M., Vanherp, L., Fernandez, N. G., de la Fuente, L. G., et al. (2024) · eLife · doi:10.7554/elife.89763.3 · Cited by 5 · see citing works

Can Green Tea Polyphenols Improve Phenotypes Associated With Down Syndrome?

Roper, R. J., & Goodlett, C. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813008-7.00035-7 · Cited by 5 · see citing works

DnaK promotes autophosphorylation of DYRK1A and its family kinases in Escherichia coli-based cell-free protein expression

Aoyama, M., Kimura, N., Yamakawa, M., Suzuki, S., Umezawa, K., & Kii, I. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149220 · Cited by 4 · see citing works

Using mouse models to understand Alzheimer's disease mechanisms in the context of trisomy of chromosome 21

Cannavo, C., Tosh, J., Fisher, E., & Wiseman, F. K. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.004 · Cited by 4 · see citing works

Tau Isoform-Regulated Schwann Cell Proliferation and Migration Improve Peripheral Nerve Regeneration After Injury

Li, S., Zhang, F., Wang, G., Liu, Q., Wang, X., Chen, Q., & Chu, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212352 · Cited by 3 · see citing works

Identification and Validation of an Inhibitor of the Protein Kinases PIM and DYRK

Bencze, G., Venkataramani, P., Elkayam, E., Rivera, K. D., Garg, A., Szabadakai, I., Őrfi, L., Joshua‐Tor, L., Pappin, D., & Tonks, N. K. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03226 · Cited by 3 · see citing works

Regulation of neuronal mRNA splicing and Tau isoform ratio by ATXN3 through deubiquitylation of splicing factorsPreprint

Neves‐Carvalho, A., Duarte‐Silva, S., Silva, J. M., Meireles-Costa, L., Monteiro‐Fernandes, D., Correia, J. S., Rodrigues, B., Heetveld, S., Almeida, B., Savytska, N., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/711424 · Cited by 3 · see citing works

DYRK1A and Parkinson’s disease, facts and hypotheses

Meijer, L., Lindberg, M. F., Hogrel, G., & Khor, B. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107379 · Cited by 2 · see citing works

Cholinergic System Structure and Function Changes in Individuals with Down Syndrome During the Development of Alzheimer’s Disease

Russell, J. K., Conley, A. C., Wilson, J. E., & NEWHOUSE, P. A. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_523 · Cited by 2 · see citing works

Down syndrome: a model for chromosome abnormalities

Overk, C., & Mobley, W. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00007-1 · Cited by 2 · see citing works

Tau in Health and Neurodegenerative Diseases

Chu, D., & Liu, F. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.101299 · Cited by 2 · see citing works

Craniofacial dysmorphology in Down Syndrome is caused by increased dosage of Dyrk1a and at least three other genesPreprint

Redhead, Y. T., Gibbins, D., Lana‐Elola, E., Watson-Scales, S., Dobson, L., Krause, M., Liu, K. J., Fisher, E., Green, J. B. A., & Tybulewicz, V. L. J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.27.497841 · Cited by 2 · see citing works

Bibliometric analysis of the interplay between Alzheimer's disease and type 2 diabetes mellitus: Trends, hotspots, and emerging research areas

Cheng, M., Wei, Y.-D., Zheng, X., Gao, X., Sun, H., & Ge, J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251351042 · Cited by 1 · see citing works

Targeting dual specificity tyrosine-phosphorylation-regulated kinase 1A mitigates tauopathy and enhances recovery after repetitive head injury

Melchior, B., Browning, M., McCartan, R., Lai, C., Hahn-Townsend, C., Gratkowski, A., Morin, A., MULLAN, M. J., Crawford, F., Grifman, M., et al. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00843 · Cited by 1 · see citing works

Epigallocatechin-3-gallate

Stagni, F., Guidi, S., & Bartesaghi, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817986-4.00053-5 · Cited by 1 · see citing works

Oxidative stress and mTOR in Down syndrome brain: Link to Alzheimer's dysmetabolism, neuropathology, and possible therapies

Marzia Perluigi, A., Domenico, F. D., & Butterfield, D. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818845-3.00009-8 · Cited by 1 · see citing works

Tau in Tauopathies That Leads to Cognitive Disorders and in Cancer

Huda, M. N., & Pan, C. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.74025 · Cited by 1 · see citing works

Genetic mapping of APP and amyloid-β biology modulation by trisomy 21Preprint

Mumford, P., Tosh, J., Anderle, S., Gkanatsiou, E., Lau, G., Noy, S., Cleverley, K., Saito, T., Saido, T. C., Yu, E. Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.10.483782 · Cited by 1 · see citing works

Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse model

Llambrich, S., Tielemans, B., Saliën, E., Atzori, M., Wouters, K., Bulck, V. V., Platt, M., Vanherp, L., Fernandez, N. G., de la Fuente, L. G., et al. (2023) · eLife · doi:10.1101/2023.07.31.551282 · Cited by 6 · see citing works

Dyrk1a inhibition with the Novel Compound DYR533: A Cross-Disease Therapeutic Strategy Targeting Amyloidosis, Tau Pathogenesis, and NeuroinflammationPreprint

Bartholomew, S. K., Turk, J., Winslow, W., Foley, C., Shaw, A. Y., Rokey, S., Tallino, S., Judd, J. M., Beach, T. G., Serrano, G. E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.20.700091 · Cited by 1 · see citing works

Single Molecule Imaging Reveals Tau Structure And Function On The Microtubule Surface

Stern, J. L. (2018) · ScholarWorks -A service of University of Vermont Libraries (University of Vermont)

Cognitive function in mice with segmental trisomy of human chromosome 21 Down Syndrome genes

Canonica, T. (2019) · ORCA Online Research @Cardiff (Cardiff University)

Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase‐1A (DYRK1A), A Master Regulatory Protein Involved in Down Syndrome Brain Alterations and Mental Disability, A Key Contributor to Neurodegenerative Disorders of Alzheimer's Disease and A Potential Therapeutic Target

Rachidi, M. (2022) · International Journal of Neurodegenerative Disorders · doi:10.23937/2643-4539/1710023

Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse modelPreprint

Llambrich, S., Tielemans, B., Saliën, E., Atzori, M., Wouters, K., Bulck, V. V., Platt, M., Vanherp, L., Fernandez, N. G., de la Fuente, L. G., et al. (2023) · eLife · doi:10.7554/elife.89763.1

Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse modelPreprint

Llambrich, S., Tielemans, B., Saliën, E., Atzori, M., Wouters, K., Bulck, V. V., Platt, M., Vanherp, L., Fernandez, N. G., de la Fuente, L. G., et al. (2024) · eLife · doi:10.7554/elife.89763.2

Revisión sistemática de las complicaciones perinatales en el síndrome de Down y su abordaje genético

Valencia, S. C., Vallejo, M. C., Beltrán, N., Rodríguez, L. M., García, S. N., González, J. G., Gómez, E. G., & Castañeda, J. E. Q. (2025) · Revista Salud Bosque · doi:10.18270/rsb.4825

A Comprehensive Investigation on the Role of Bioactives on DYRK1A to Avert Alzheimer’s Disease

Sharma, M., Mazumder, R., Padhi, S., & Shivangi, K. (2025) · Journal of Natural Remedies · doi:10.18311/jnr/2025/49903

Novel small-molecule inhibitors of the protein kinase DYRK: Potential therapeutic candidates in cancerPreprint

Venkataramani, P., Elkayam, E., Garg, A., Cheng, K. F., Altiti, A. S., He, M., Thakur, K., Michalopoulou, E., Gonzalez, C., Felice, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.05.686653

HMW-3R-tau Promotes Axon Growth and Regeneration in Peripheral Neurons

Chu, D., Zhang, F., Zhang, J., Chen, Y., Wang, X., Zhang, F., Yi, S., Chen, Q., & Li, S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05366-7

Novel FUS and CHCHD10 models to investigate pathogenic mechanisms in Amyotrophic Lateral Sclerosis

Bourefis, A.-R. (2019) · theses.fr (ABES) · doi:10.70675/45ab8515z9859z430fzb472z306dd61206c8

Caractérisation des mécanismes moléculaires impliqués dans la mise en place des altérations cérébrales dans un modèle préclinique de diabète de type 2

Hamzé, R. (2023) · theses.fr (ABES) · doi:10.70675/3ac7f72cz196fz4796z99a3z89271cd76677

Machine Learning-Driven Ensemble Screening of Multitarget Kinase Inhibitors for Tauopathy-Associated Neurodegeneration Using All-Atom and Steered MD Simulations

Choudhury, A., Saeed, M. U., Prabha, S., & Hassan, M. I. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00097

Small-molecule inhibitors of the protein kinase DYRK as potential therapeutic candidates in cancer

Venkataramani, P., Elkayam, E., Garg, A., Cheng, K. F., Altiti, A. S., He, M., Thakur, K., Michalopoulou, E., Gonzalez, C., Felice, C., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.05.005

Splicing kinases in neuronal health and neurodegeneration

El‐Gamil, D. S., Emad, M., Darwish, S. S., Hwang, T., Abadi, A. H., Engel, M., & Abdel‐Halim, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44173-8.00022-x

Integrative Insights Into DYRK1A From Molecular Function to Therapeutic Advancement

Paul, S., Dubey, S., & Tiwari, P. (2026) · Chemical Biology and Drug Design · doi:10.1111/cbdd.70366

DYRK1A – a gene dose paradox

Plećaš, A., Gough, G., Kunštek, S., Babić, M., Murray, A., Nižetić, D., & Alić, I. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1963992

BindingDB Entry 50020570: Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer's Disease Drug Candidate.

BindingDB (2024) · UC San Diego · doi:10.7270/q2mg7v01

BindingDB Entry 50018840: Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases.

BindingDB (2024) · UC San Diego · doi:10.7270/q2x92gjt

BindingDB Entry 50018911: DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.

BindingDB (2024) · UC San Diego · doi:10.7270/q26d5z77

BindingDB Entry 50016416: Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors.

BindingDB (2023) · UC San Diego · doi:10.7270/q2fn1b7v

P1‐350: Overexpression of Dyrk1A dysregulates the alternative splicing of tau exon 10

Yin, X., Shi, J., Grundke, I., Iqbal, K., Gong, C., & Liu, F. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.05.903

S1‐03–05: Increased dosage of Dyrk1A alters the alternative splicing of Tau exon 10 in Down syndrome

Liu, F. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.201

O2‐12‐03: Regulation of alternative splicing of tau exon 10 by dual‐specificity tyrosine‐phosphorylation‐regulated kinase 1A

Liu, F., Jin, N., Yin, X., Gu, J., Qian, W., Gong, C., & Iqbal, K. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.07.197

Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down Syndrome

Shi, J., Zhang, T., Zhou, C., Chohan, M. O., Gu, X., Węgiel, J., Zhou, J., Hwang, Y., Iqbal, K., Grundke, I., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802645200 · Cited by 179 · see citing works

doi:10.1093/nar/gkr195 Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A

Qian, W., Liang, H., Shi, J., Jin, N., Grundke, I., Iqbal, K., Gong, C.-X., & Liu, F. (2010)